疏肝益肾颗粒联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎的临床研究

Clinical Study on Shugan Yishen Granule Combined with Entecavir in the Treatment of HBeAg-positive Chronic Hepatitis B

目的探讨疏肝益肾颗粒联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎的临床疗效。方法选取符合入组标准的HBeAg阳性慢性乙型肝炎患者60例,随机分为联合治疗组(疏肝益肾颗粒联合恩替卡韦)和单药治疗组(恩替卡韦),疗程6个月,观察2组患者ALT、HBV-DNA、HBeAg的变化。结果治疗12周、24周后2组ALT、HBV-DNA、HBeAg比较,联合治疗组ALT复常率、HBV-DNA转阴率、HBeAg转阴率均高于单药治疗组。P<0.05,具有统计学意义。结论疏肝益肾颗粒联合恩替卡韦治疗HBeAg阳性CHB的临床效率确切,可显著降低ALT,抑制HBV复制,促进HBeAg转阴,无不良反应,安全性高。

Objective To explore the clinical efficacy of Shugan Yishen granule combined with entecavir in the treatment of HBeAg-positive chronic hepatitis B.Methods Sixty patients with HBeAg-positive chronic hepatitis B who met the admission criteria in our hospital were randomly divided into a combination therapy group(Shugan Yishen granules combined with entecavir)and monotherapy group(entecavir)for 6 months.Changes in ALT,HBV-DNA,and HBeAg in the two groups were observed.Results After 12 weeks and 24 weeks of treatment,ALT,HBV-DNA and HBeAg were compared between the two groups P<0.05,and the difference was statistically significant.The ALT recurrence rate,HBV-DNA negative rate and HBeAg negative rate in the combined treatment group were higher than those in the monotherapy.Conclusion The clinical efficiency of Shugan Yishen granule combined with entecavir in the treatment of HBeAg-positive CHB is significant,which can significantly reduce ALT,inhibit HBV replication,promote HBeAg conversion,and has no adverse reactions and high safety.